Journal of Advanced Medical and Dental Sciences Research

@Society of Scientific Research and Studies NLM ID: 101716117

Journal home page: www.jamdsr.com

doi: 10.21276/jamdsr

Index Copernicus value = 91.86

(e) ISSN Online: 2321-9599; (p) ISSN Print: 2348-6805

Original Research

To study Effect of ropivacaine and bupivacaine on heart rate for supraclavicular brachial plexus

Suneel Kumar Garg

Assistant Professor, Department of Anaesthesia, Noida International Institute of Medical Sciences, Greater Noida, U.P., India

ABSTRACT:

Aim: To study Effect of ropivacaine and bupivacaine on heart rate for supraclavicular brachial plexus. **Methods:** 50 patients aged 20-60 years, weighing more than 50 kgs were taken up for the study. Patients were kept Nil per orally for 6 hours before the time of surgery and on the previous night premedicated with Diazepam 5 mg and Ranitidine 150mg. 50 patients ASA I and ASA II were randomly allocated with sealed envelope method into two different groups of 25 each. Both observer and participant were blinded. Group A: Received (n=25) 25 ml of 0.5% bupivacaine and Group B: Received (n=25) 25 ml of 0.5% ropivacaine. **Results:** Gender distribution in both groups was comparable. There is no statistically significant difference. Two groups were comparable with respect to their age, gender and weight. There was no statistically significant difference in heart rate between both groups (p>0.05). There is no significant difference of heart rate clinically. **Conclusion:** There was no statistically significant difference in heart rate clinically.

Received: 12 October, 2021 Accepted: 17 November, 2021

Corresponding author: Suneel Kumar Garg, Assistant Professor, Department of Anaesthesia, Noida International Institute of Medical Sciences, Greater Noida, U.P., India

This article may be cited as: Garg SK. To study Effect of ropivacaine and bupivacaine on heart rate for supraclavicular brachial plexus. J Adv Med Dent Scie Res 2021;9(12):153-155.

INTRODUCTION

Ever since William Stewart Halsted and Richard John Hall first reported the use of cocaine to block upper extremity nerves in 1884, brachial plexus regional anaesthesia has been used extensively by anaesthesiologists worldwide. Supraclavicular block is preferred procedure for hand and fore-arm surgeries, as it is safe, has rapid onset and gives reliable anaesthesia. Success rates are better when a nerve stimulator is used as a clear response of the fingers is obtained at a seeking current which indicates a close proximity to the plexus. ²

Various local anaesthetic agents and adjuvants are used for this purpose. Among them, bupivacaine has been the most widely used long-acting local anaesthetic agent. However, bupivacaine is associated with various CNS and cardiac side effects and unintended intravascular injection of bupivacaine lead to cardiac arrest, prolonged resuscitation and a disproportionally high number of deaths.^{3,4} In search of better alternative, ropivacaine has been proposed as a promising drug with fewer cardiovascular and central nervous system toxic effects compared with

bupivacaine.⁵ Researchers have demonstrated lesser cardiac depression and fewer CNS effects when ropivacaine is injected intravenously. ⁶

MATERIAL AND METHODS

This comparative study was carried out, after taking the approval of the protocol review committee and institutional ethics committee. 50 patients aged 20-60 years, weighing more than 50 kgs were taken up for the study. All the patients were evaluated thoroughly on the previous day of the surgery. A detailed history, complete physical examination and routine investigations were done for all patients were explained about procedure. Patients between ages 20-60yrs undergoing elective upper limb surgeries.

ASA class 1 and 2 and No history of allergy or sensitivity to above mentioned drugs were included in this study. Uncooperative and unwilling patient, Hypersensitivity to Drugs, History of neurologic or seizure disorder and ASA grade III and IV were excluded from the study.

Patients were kept Nil per orally for 6 hours before the time of surgery and on the previous night premedicated with Diazepam 5 mg and Ranitidine 150mg. 50 patients ASA I and ASA II were randomly allocated with sealed envelope method into two different groups of 25 each. Both observer and participant were blinded.

Group A: Received (n=25) 25 ml of 0.5% bupivacaine.

Group B: Received (n=25) 25 ml of 0.5% ropivacaine.

RESULTS

Table 1: Basic parameter

			Gro	Total	
			Bupivacaine	Ropivacaine	
	F	Count	9	6	15
Gender		% within Group	18%	12%	30%
	M	Count	15	20	35
		% within Group	30%	40%	70%

Gender distribution in both groups was comparable. There is no statistically significant difference. Two groups were comparable with respect to their age, gender and weight.

Table 2: Heart rate between two groups

0 BUPIVACAINE ROPIVACAINE 25 60.00 1.91 0.78 28 0.43 5 BUPIVACAINE 25 59.66 1.39 0.29 28 0.76 ROPIVACAINE 25 59.90 1.44 1.18 28 0.24 10 BUPIVACAINE 25 59.90 1.44 1.18 28 0.24 ROPIVACAINE 25 60.26 1.68 -0.85 28 0.4 ROPIVACAINE 25 60.26 1.68 -0.85 28 0.4 ROPIVACAINE 25 60.20 1.74 1.98 28 0.05 ROPIVACAINE 25 60.60 1.45 1.98 28 0.05 45 BUPIVACAINE 25 60.40 1.35 1.35 0.19 45 BUPIVACAINE 25 60.76 1.61 1.32 28 0.19 60 BUPIVACAINE 25 60.80 1.88 0.73 28 0.45 <th>HR IN MIN</th> <th>GROUP</th> <th>N</th> <th>Mean</th> <th>Std. Deviation</th> <th>T</th> <th>Df</th> <th>P Value</th>	HR IN MIN	GROUP	N	Mean	Std. Deviation	T	Df	P Value
5 BUPIVACAINE ROPIVACAINE 25 60.03 2.09 0.29 28 0.76 10 BUPIVACAINE 25 59.90 1.44 1.18 28 0.24 10 BUPIVACAINE 25 60.26 1.85 1.18 28 0.24 15 BUPIVACAINE 25 60.26 1.68 -0.85 28 0.4 ROPIVACAINE 25 60.60 1.45 1.98 28 0.05 30 BUPIVACAINE 25 60.60 1.45 1.98 28 0.05 45 BUPIVACAINE 25 60.40 1.35 1.32 28 0.19 45 BUPIVACAINE 25 60.16 1.57 1.61 1.32 28 0.19 60 BUPIVACAINE 25 60.61 1.57 0.14 28 0.88 80PIVACAINE 25 60.63 1.69 0.14 28 0.88 120 BUPIVACAINE 25 60.60 1.77 0.42 28 0.67 150 BUPIVACAINE	0	BUPIVACAINE	25	60.00	1.91	0.78	28	0.43
ROPIVACAINE 25 59.90 1.44 1.85 1.18 28 0.24 ROPIVACAINE 25 60.26 1.85 1.18 28 0.24 ROPIVACAINE 25 59.73 1.43 1.43 1.44 1.55 ROPIVACAINE 25 60.26 1.68 -0.85 28 0.4 ROPIVACAINE 25 60.60 1.45 1.98 28 0.05 ROPIVACAINE 25 60.40 1.35 1.32 28 0.19 ROPIVACAINE 25 60.40 1.35 1.32 28 0.19 ROPIVACAINE 25 60.60 1.88 0.73 28 0.45 ROPIVACAINE 25 60.63 1.88 0.73 28 0.45 ROPIVACAINE 25 60.63 1.35 1.35 1.35 ROPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.60 1.47 1.70 1.20 ROPIVACAINE 25 60.60 1.77 1.20 ROPIVACAINE 25 60.60 1.77 1.20 ROPIVACAINE 25 60.60 1.77 1.20 ROPIVACAINE 25 60.60 1.42 1.13 28 0.26 ROPIVACAINE 25 60.60 1.42 1.13 28 0.26 ROPIVACAINE 25 60.40 1.24 1.50 28 0.14 ROPIVACAINE 25 60.40 1.24 240 ROPIVACAINE 25 60.93 1.08 1.08 ROPIVACAINE 25 60.93 1.08 300 ROPIVACAINE 25 60.7665 1.22 360 ROPIVACAINE 25 60.16 1.46 1.29 28 0.20 ROPIVACAINE 25 60.16 1.41 1.40 ROPIVACAINE 25 60.10 1.60 ROPIVACAINE 25 60.10 1.60 ROPIVACAINE 25 60.10 1.60 1.41 28 0.93 ROPIVACAINE 25 60.10 1.60 1.41 1.41 28 0.93 ROPIVACAINE 25 60.10 1.31 1.41 28 0.93 ROPIVACAINE 25 60.7665 1.22 360 ROPIVA		ROPIVACAINE	25	59.66	1.39			
10	5	BUPIVACAINE	25	60.03	2.09	0.29	28	0.76
ROPIVACAINE 25 59.73 1.43		ROPIVACAINE	25	59.90	1.44			
15 BUPIVACAINE 25 60.26 1.68 -0.85 28 0.4 ROPIVACAINE 25 60.60 1.45 1.45 1.98 28 0.05 ROPIVACAINE 25 61.20 1.74 1.98 28 0.05 ROPIVACAINE 25 60.40 1.35 1.35 1.35 1.35 1.35 45 BUPIVACAINE 25 60.76 1.61 1.32 28 0.19 ROPIVACAINE 25 60.16 1.57 1.30 1.35 1.35 60 BUPIVACAINE 25 60.80 1.88 0.73 28 0.45 ROPIVACAINE 25 60.63 1.35 1.35 1.35 90 BUPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.60 1.47 1.40 1.60 120 BUPIVACAINE 25 60.60 1.77 1.70 150 BUPIVACAINE 25 60.60 1.77 1.70 150 BUPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 60.40 1.24 1.50 28 0.14 240 BUPIVACAINE 25 60.40 1.24 240 BUPIVACAINE 25 60.40 1.24 240 BUPIVACAINE 25 60.93 1.08 300 BUPIVACAINE 25 60.7665 1.22 360 BUPIVACAINE 25 60.7665 1.31 420 BUPIVACAINE 25 60.70 1.31 1.41 28 0.16 ROPIVACAINE 25 60.70 1.31 1.41 28 0.57 480 BUPIVACAINE 25 60.70 1.72 0.56 28 0.57	10	BUPIVACAINE	25	60.26	1.85	1.18	28	0.24
ROPIVACAINE 25 60.60 1.45 1.98 28 0.05 ROPIVACAINE 25 61.20 1.74 1.98 28 0.05 ROPIVACAINE 25 60.40 1.35 1.32 28 0.19 ROPIVACAINE 25 60.76 1.61 1.32 28 0.19 ROPIVACAINE 25 60.16 1.57 1.32 28 0.45 ROPIVACAINE 25 60.80 1.88 0.73 28 0.45 ROPIVACAINE 25 60.63 1.35 1.47 1.20 BUPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.80 1.62 0.42 28 0.67 ROPIVACAINE 25 60.60 1.77 1.70 1.50 BUPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 61.10 1.60 1.60 1.50 28 0.14 ROPIVACAINE 25 60.40 1.24 1.20 28 0.23 ROPIVACAINE 25 60.93 1.08 1.08 300 BUPIVACAINE 25 60.93 1.08 300 BUPIVACAINE 25 60.7665 1.22 360 BUPIVACAINE 25 60.7665 1.22 360 BUPIVACAINE 25 61.16 1.46 1.29 28 0.20 ROPIVACAINE 25 61.60 1.41 360 ROPIVACAINE 25 61.60 1.41 37 38 38 38 38 38 38 38		ROPIVACAINE	25	59.73	1.43			
30 BUPIVACAINE 25 61.20 1.74 1.98 28 0.05 ROPIVACAINE 25 60.40 1.35 1.32 28 0.19 ROPIVACAINE 25 60.76 1.61 1.32 28 0.19 ROPIVACAINE 25 60.16 1.57 28 0.45 ROPIVACAINE 25 60.80 1.88 0.73 28 0.45 ROPIVACAINE 25 60.83 1.35 28 0.45 ROPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.80 1.62 0.42 28 0.67 ROPIVACAINE 25 60.60 1.77 150 BUPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 61.10 1.60 1.60 180 BUPIVACAINE 25 61.30 1.62 1.50 28 0.14 ROPIVACAINE 25 60.40 1.24 240 BUPIVACAINE 25 61.36 1.79 1.20 28 0.23 ROPIVACAINE 25 60.7665 1.22 360 BUPIVACAINE 25 61.16 1.46 1.29 28 0.20 ROPIVACAINE 25 61.10 1.60 0.07 28 0.93 ROPIVACAINE 25 61.06 1.41 420 BUPIVACAINE 25 61.26 1.33 480 BUPIVACAINE 25 61.26 1.33 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57	15	BUPIVACAINE	25	60.26	1.68	-0.85	28	0.4
ROPIVACAINE 25 60.40 1.35		ROPIVACAINE	25	60.60	1.45			
Supivacaine 25 60.76 1.61 1.32 28 0.19	30	BUPIVACAINE	25	61.20	1.74	1.98	28	0.05
ROPIVACAINE 25 60.16 1.57 60 BUPIVACAINE 25 60.80 1.88 0.73 28 0.45 ROPIVACAINE 25 60.53 1.35 0.14 28 0.88 90 BUPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.60 1.47 0.42 28 0.67 ROPIVACAINE 25 60.80 1.62 0.42 28 0.67 ROPIVACAINE 25 60.60 1.77 0.42 28 0.67 BUPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 61.10 1.60 1.50 28 0.14 ROPIVACAINE 25 61.03 1.62 1.50 28 0.23 ROPIVACAINE 25 61.36 1.79 1.20 28 0.23 ROPIVACAINE 25 61.16 1.46 1.29<		ROPIVACAINE	25	60.40	1.35			
60 BUPIVACAINE ROPIVACAINE 25 60.80 1.88 0.73 28 0.45 90 BUPIVACAINE 25 60.53 1.35 0.14 28 0.88 ROPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.56 1.47 0.42 28 0.67 ROPIVACAINE 25 60.80 1.62 0.42 28 0.67 ROPIVACAINE 25 60.60 1.77 0.42 28 0.26 ROPIVACAINE 25 61.10 1.60 0.42 28 0.26 ROPIVACAINE 25 61.03 1.62 1.50 28 0.14 ROPIVACAINE 25 60.40 1.24 0.20 0.23 ROPIVACAINE 25 60.93 1.08 0.23 0.23 300 BUPIVACAINE 25 60.7665 1.22 0.20 ROPIVACAINE 25 61.16 1.46 1.29 28 0.20 ROPIVACAINE 25 61.06 1.41 0.07	45	BUPIVACAINE	25	60.76	1.61	1.32	28	0.19
ROPIVACAINE 25 60.53 1.35 90 BUPIVACAINE 25 60.63 1.69 0.14 28 0.88 ROPIVACAINE 25 60.56 1.47 0.14 28 0.88 120 BUPIVACAINE 25 60.56 1.47 0.42 28 0.67 ROPIVACAINE 25 60.60 1.77 0.42 28 0.67 ROPIVACAINE 25 60.60 1.77 0.13 28 0.26 ROPIVACAINE 25 61.10 1.60 0.28 0.14 ROPIVACAINE 25 61.33 1.62 1.50 28 0.14 ROPIVACAINE 25 61.36 1.79 1.20 28 0.23 ROPIVACAINE 25 60.93 1.08 1.08 0.20 ROPIVACAINE 25 61.16 1.46 1.29 28 0.20 ROPIVACAINE 25 61.10 1.60 0.07 28 0.9		ROPIVACAINE		60.16	1.57			
90 BUPIVACAINE ROPIVACAINE 25 60.63 1.69 0.14 28 0.88 120 BUPIVACAINE 25 60.56 1.47 0.42 28 0.67 ROPIVACAINE 25 60.80 1.62 0.42 28 0.67 ROPIVACAINE 25 60.60 1.77 -1.13 28 0.26 ROPIVACAINE 25 61.10 1.60 -1.13 28 0.26 ROPIVACAINE 25 61.03 1.62 1.50 28 0.14 ROPIVACAINE 25 60.40 1.24 -1.20 28 0.23 ROPIVACAINE 25 60.93 1.08 -1.20 28 0.23 300 BUPIVACAINE 25 60.7665 1.22 -1.20 28 0.20 ROPIVACAINE 25 60.7665 1.22 -1.20 28 0.93 ROPIVACAINE 25 61.10 1.60 0.07 28 0.93 ROPIVACAINE 25 61.06 1.41 -1.41 28 0.16 R	60	BUPIVACAINE	25	60.80	1.88	0.73	28	0.45
ROPIVACAINE 25 60.56 1.47		ROPIVACAINE	25	60.53	1.35			
120	90	BUPIVACAINE	25	60.63	1.69	0.14	28	0.88
ROPIVACAINE 25 60.60 1.77 150 BUPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 61.10 1.60 1.50 28 0.14 ROPIVACAINE 25 61.03 1.62 1.50 28 0.14 ROPIVACAINE 25 60.40 1.24 1.20 28 0.23 ROPIVACAINE 25 60.93 1.08 1.08 300 BUPIVACAINE 25 61.16 1.46 1.29 28 0.20 ROPIVACAINE 25 60.7665 1.22 360 BUPIVACAINE 25 61.10 1.60 0.07 28 0.93 ROPIVACAINE 25 61.06 1.41 420 BUPIVACAINE 25 61.70 1.31 1.41 28 0.16 ROPIVACAINE 25 61.26 1.33 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57		ROPIVACAINE	25	60.56	1.47			
BUPIVACAINE 25 60.63 1.42 -1.13 28 0.26 ROPIVACAINE 25 61.10 1.60 1.50 28 0.14 ROPIVACAINE 25 60.40 1.24 240 BUPIVACAINE 25 60.40 1.24 240 ROPIVACAINE 25 60.93 1.08 300 BUPIVACAINE 25 60.7665 1.22 360 BUPIVACAINE 25 60.7665 1.22 360 BUPIVACAINE 25 61.10 1.60 0.07 28 0.93 ROPIVACAINE 25 61.06 1.41 420 BUPIVACAINE 25 61.70 1.31 1.41 28 0.16 ROPIVACAINE 25 61.26 1.33 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57 480 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57 480	120	BUPIVACAINE	25	60.80	1.62	0.42	28	0.67
ROPIVACAINE 25 61.10 1.60		ROPIVACAINE	25	60.60	1.77			
180 BUPIVACAINE ROPIVACAINE 25 61.03 1.62 1.50 28 0.14 240 BUPIVACAINE 25 60.40 1.24 1.20 28 0.23 ROPIVACAINE 25 61.36 1.79 1.20 28 0.23 300 BUPIVACAINE 25 60.93 1.08 1.29 28 0.20 ROPIVACAINE 25 60.7665 1.22 28 0.20 360 BUPIVACAINE 25 61.10 1.60 0.07 28 0.93 ROPIVACAINE 25 61.06 1.41 1.41 28 0.16 ROPIVACAINE 25 61.26 1.33 1.41 28 0.16 ROPIVACAINE 25 62.00 1.72 0.56 28 0.57	150	BUPIVACAINE	25	60.63	1.42	-1.13	28	0.26
ROPIVACAINE 25 60.40 1.24		ROPIVACAINE	25	61.10	1.60			
240 BUPIVACAINE ROPIVACAINE 25 61.36 1.79 1.20 28 0.23 300 BUPIVACAINE ROPIVACAINE 25 61.16 1.46 1.29 28 0.20 360 BUPIVACAINE ROPIVACAINE ROPIVACAIN	180	BUPIVACAINE	25	61.03	1.62	1.50	28	0.14
ROPIVACAINE 25 60.93 1.08		ROPIVACAINE	25	60.40	1.24			
300 BUPIVACAINE ROPIVACAINE 25 61.16 1.46 1.29 28 0.20 360 BUPIVACAINE 25 60.7665 1.22 0.07 28 0.93 ROPIVACAINE 25 61.06 1.41 0.07 28 0.93 420 BUPIVACAINE 25 61.70 1.31 1.41 28 0.16 ROPIVACAINE 25 61.26 1.33 0.56 28 0.57 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57	240	BUPIVACAINE	25	61.36	1.79	1.20	28	0.23
ROPIVACAINE 25 60.7665 1.22		ROPIVACAINE	25	60.93	1.08			
360 BUPIVACAINE 25 61.10 1.60 0.07 28 0.93 ROPIVACAINE 25 61.06 1.41 1.41 28 0.16 420 BUPIVACAINE 25 61.70 1.31 1.41 28 0.16 ROPIVACAINE 25 61.26 1.33	300	BUPIVACAINE	25	61.16	1.46	1.29	28	0.20
ROPIVACAINE 25 61.06 1.41 420 BUPIVACAINE 25 61.70 1.31 1.41 28 0.16 ROPIVACAINE 25 61.26 1.33 1.41 28 0.16 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57		ROPIVACAINE	25	60.7665	1.22			
420 BUPIVACAINE 25 61.70 1.31 1.41 28 0.16 ROPIVACAINE 25 61.26 1.33 1.41 28 0.16 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57	360	BUPIVACAINE	25	61.10	1.60	0.07	28	0.93
ROPIVACAINE 25 61.26 1.33 480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57		ROPIVACAINE	25	61.06	1.41			
480 BUPIVACAINE 25 62.00 1.72 0.56 28 0.57	420	BUPIVACAINE	25	61.70	1.31	1.41	28	0.16
		ROPIVACAINE	25	61.26	1.33			
ROPIVACAINE 25 61.73 1.38	480	BUPIVACAINE	25	62.00	1.72	0.56	28	0.57
		ROPIVACAINE	25	61.73	1.38			

There was no statistically significant difference in heart rate between both groups (p>0.05). There is no significant difference of heart rate clinically.

DISCUSSION

Brachial plexus block has long been considered a safe method when proper technique is followed, which includes monitoring and patient selection. However, being a very vascular area, brachial plexus blockade can set a potential place for absorption of local anaesthetics and the development of systemic toxicity. Worldwide, long acting bupivacaine has been the most popular local anaesthetic for supraclavicular block in patients undergoing elective upper limb surgeries. But the CNS and CVS side effects are its limitations. Ropivacaine is the product of an intensive search for a safer alternative to bupivacaine. Although safe, ropivacaine is found to be less potent than bupivacaine and has a slightly shorter duration of action along with some motor sparing qualities. Ropivacaine has been extensively studied as an effective drug for labor analgesia and it has proved that it is comparable to bupivacaine in its efficacy with least side effect. 9,10

In 1964, Winnie showed that the relation of the plexus and the subclavian artery to the midpoint of the first rib is not constant. He showed that there is a constant relationship between the anterior and middle scalene muscles, the plexus and the first rib. He inserted needle between the two muscles in the direction of space between them. Once a paraesthesia is obtained, a single injection is made into the space.¹¹

In 1955, Pearson demonstrated that motor nerves could be located by electrical stimulation with an insulated needle. In 1969, Wright reported the block aid monitor for nerve blocks which popularized the technique making it more feasible.

Mohan IR et al. (2018) did a study on 60 patients who were scheduled for elective upper limb surgeries. They were divided into two groups. Group B received Bupivacaine 0.5% and group R received Ropivacaine 0.5%. They concluded that at equalvolumes Bupivacaine 0.5% has an advantage over Ropivacaine 0.5% for Supraclavicular Brachial Plexus block in terms of early onset of blockade and prolonged duration of blockade. 12

Kundalwalet al. (2018) conducted a prospective randomized double blind study on 100 patients, where group B received bupivacaine and group R received ropivacaine by supraclavicular brachial plexus block. The onset of sensory block was earlier in ropivacaine and the duration of block is more in bupivacaine. In terms of analgesic effect ropivacaine was better. ¹³

Modak S et al. (2016) conducted a prospective double blind randomized study involving 0 patients. They were randomly divided into two groups in which supraclavicular brachial plexus block was done using 30 ml of ropivacaine 0.5% and bupivacaine 0.5%. Ropivacaine had earlier onset of sensory and motor blockade compared to Bupivacaine. The duration of block was longer in ropivacaine. No statistically significant difference between two groups.¹ Gonuguntla SB (2016) conducted a study of total 60 patients between 20 and 60 years age of either sex scheduled for upper limb surgeries. They randomly divided into Group A(Bupivacaine)and group B(Ropivacaine). He concluded that there were no much clinical differences in onset, duration and analgesia among bupivacaine and ropivacaine when injected in equal volumes for brachial plexus block by the supraclavicular approach.¹⁵

CONCLUSION

There was no statistically significant difference in heart rate between both groups (p>0.05). There is no significant difference of heart rate clinically.

REFERENCES

- 1. Hall RJ. Hydrochlorate of cocaine. N Y Med J. 1884;40:643-46.
- Pither C, Ford D, Raj P. Peripheral nerve stimulation with insulated and uninsulated needles: Efficacy of characteristics. Reg Anaesth.
- 1984;9:73-77. Mazoit JX, Boico O, Samii K. Myocardial uptake of bupivacaine: II. Pharmacokinetics and pharmacodynamics of bupivacaine enantiomers in the isolated perfused rabbit heart. Anaesth Analg. 1993;77:477-82.
- Mazoit JX, Decaux A, Bouaziz H, Edouard A. Comparative ventricular electrophysiologic effect of racemic bupivacaine, levobupivacaine, and ropivacaine on the isolated rabbit heart. Anaesthesiology. 2000;93:784–92.
- Scott DB, Lee A, Fagan D, Bowler GMR, Bloomfield P, Lundh R. Acute toxicity of ropivacaine compared with that of bupivacaine. Anaesth Analg.
- 1989;69:563-69. Arthur GR, Feldman HS, Covino BG. Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anaesthetic. Anaesth Analg. 1988;67:1053–58.
- Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian Journal of Anaesthesia. 2011;55(2):104-10.
- Malachy C, Maclennan K. Local anaesthetic agents. Anaesthesia & Intensive Care Medicine. 2007;8:159–62.
- 9. Dresner M, Freeman J, Calow C, Quinn A, Bamber J. Ropivacaine 0.2% versus bupivacaine 0.1% with fentanyl: a double blind comparison for analgesia during labour. Br J Anaesth. 2000;85(6):826-29.
- Capogna G, Cellena D, Fusco P, Lyons G, Columb M. Relative potencies of bupivacaine and ropivacaine for analgesia in labour. Br J Anaesth. 1999;82:371–73.
- 11. Bertini L, Tagariello V, Mancini S, Ciaschi A, Posteraro CM, Di Benedetto Pet al. 0.75% and 0.5% ropivacaine for axillary brachial plexus block: a clinical comparison with 0.5% bupivacaine. Regional anesthesia and pain medicine. 1999 Nov;24(6):514-8.
- 12. Klien SM, Greengrass RA, Steele SM. A comparison of 0.5% bupivacaine, 0.5% ropivacaine, 0.75% ropivacaine for interscalene brachial plexus block. Anaesthesia Analgesia. 1998;87:1316-91.
- Vainionpaa VA, Haavisto ET, Huha TM. A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. AnaesthAnalg. 1995;81:534-8.
- 14. Kaur A, Singh RB, Tripathi RK, Choubey S. Comparision between bupivacaine and ropivacaine in patients undergoing forearm surgeries under axillary brachial plexus block: a prospective randomized study. J Clin Diagn Res. 2015;9(1):UC01-6.
- 15. Kooloth RA, Patel SN, Mehta MK. A comparison of 0.5% Ropivacaine and 0,5% Bupivacaine in supraclavicular brachial plexus block. National Journal of Medical Research. 2015;5(1):67-70.